Latest Spliceosome Stories
Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins.
Understanding and overcoming â€˜the Warburg Effectâ€™.
AMSTERDAM, January 6 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD).
New Additions to Organization Will Focus on Research, Advocacy, and Outreach MIDDLETOWN, Ohio, Jan. 5 /PRNewswire-USNewswire/ -- Patricia A.
A team of researchers is being recognized for devising a new way to study a human protein that long has evaded close scrutiny by scientists investigating its role in the communication of important genetic messages inside a cell's nucleus to workhorse molecules found elsewhere.
TAU researchers unravel the mysteries of DNA packaging.
The sequences of nonsense DNA that interrupt genes could be far more important to the evolution of genomes than previously thought.
University of Georgia scientists looking to understand the genetic mechanisms of plant defense and growth have found for the first time in plants an inverse relationship between gene duplication and alternative splicing.
Humans and mice have previously unknown and potentially critical differences in one of the genes responsible for Duchenne muscular dystrophy (DMD).
AMSTERDAM, November 18 /PRNewswire-FirstCall/ -- - Glybera(R) Clinical Data Presented at Meeting of American Heart Association Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive.